EU approves Invokana for Type 2 Diabetes-Janssen
Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved Invokana (canagliflozin) in the European Union for the treatment of adults with Type 2 Diabetes Mellitus, to improve glycaemic control.Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.
Canagliflozin is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control; -as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications or- as add-on therapy with other anti-hyperglycaemic medicinal products including insulin, when these together with diet and exercise, do not provide adequate glycaemic control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.